(+)-Razpipadon (Synonyms: (+)-PW0464) |
Katalog-Nr.GC79286
One-Click Copy Product Info
|
(+)-Razpipadon ((+)-PW0464) is a selective D1 dopamine receptor agonist belonging to non-catechol compounds.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1643489-51-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, (+)-Razpipadon is a G protein-biased agonist of human D1R that activates the G protein signaling pathway. Its potency is slightly lower than that of Tavapadon, but it cannot effectively activate the β-arrestin pathway[1].
References:
[1]. Teng X, et al. Ligand recognition and biased agonism of the D1 dopamine receptor. Nat Commun. 2022;13(1):3186. Published 2022 Jun 8.
[2]. Sibley D R, et al. Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 205.
[3]. Kumar S, et al. Discovery and structure - activity relationships of 2,4,5-trimethoxyphenyl pyrimidine derivatives as selective D5 receptor partial agonists. Bioorg Chem. 2024;153:107809.
| Cas No. | 1643489-51-3 | SDF | |
| Überlieferungen | (+)-PW0464 | ||
| Formula | C19H17F2N3O4 | M.Wt | 389.35 |
| Löslichkeit | DMSO: 100 mg/mL (256.84 mM; Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5684 mL | 12.8419 mL | 25.6838 mL |
| 5 mM | 513.7 μL | 2.5684 mL | 5.1368 mL |
| 10 mM | 256.8 μL | 1.2842 mL | 2.5684 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)